GlassScriptPhysician profile
Kevin J Powers
NPI 1902804685
$1,208.12
in general payments reported to CMS, 2019-2025
14 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2021: $179 · 2022: $108 · 2023: $355 · 2024: $204 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Checkpoint Surgical, INC | $308.17 | 2022-2023 | Checkpoint Stimulators |
| Orthofix Medical, INC. | $191.02 | 2024-2025 | Truelok |
| Sanara Medtech INC. | $152.99 | 2021 | |
| Integra Lifesciences Corporation | $139.89 | 2023 | Tenoglide, Integra, Integra Dermal Regeneration Template |
| Paragon 28, INC. | $109.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.66 | 2024-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $78.62 | 2024-2025 | Austedo Xr, Austedo Xr |
| Globus Medical, INC. | $32.67 | 2025 | Senza |
| Musculoskeletal Transplant Foundation INC. | $26.28 | 2021 | |
| Boston Scientific Corporation | $18.84 | 2024 | Wavewriter Alpha Prime 16 |
| Smith+Nephew, INC. | $17.34 | 2025 | Collagenase Santyl |
| Bioventus LLC | $15.56 | 2022 | |
| Corium, LLC | $14.00 | 2025 | Azstarys |
| Kerecis Limited | $12.94 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.